secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001193125-24-199425
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M
--------------------------------------------------------------------------------

- UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.
- Q2 JELMYTO net revenue $21.8M (+3% YoY); full-year revenue expected at lower end of guidance range.
- Q2 net loss $33.4M ($0.91/share) vs $24.1M ($1.03/share) in Q2 2023; operating loss $25.8M.
- Cash & marketable securities $241.3M at June 30; June public offering raised $107.5M gross.
- Full-year operating expenses expected at higher end of guidance; R&D $15.4M, SG&A $30.1M in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/0001193125-24-199425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/d865545d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer